Home HOME Neoplasma 2021 Neoplasma Vol.68, No.2, p.454–464, 2021

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.68, No.2, p.454–464, 2021

Title: Economic aspects of multiple myeloma: real costs associated with disease in the Slovak Republic
Author: Robert Babela, Richard Didic, Martin Smatana, Katarina Fedorova, Lubos Drgona

Abstract: Health care costs are continuously increasing. Multiple myeloma represents approximately 1% of all malignancies and the 5-year prevalence is 230,000 patients on average. In addition, there is an annual incidence of 3.8/100,000 in Slovakia. In total economic burden assessment, it is important to focus not only on direct but also on indirect costs, including the lost productivity due to premature death. Based on the data and information obtained from the key stakeholders the Ministry of Health, the Ministry of Labor, the Social Insurance Agency, and NCZI, we provided the assessment of direct and indirect costs. The total cost of the disease for the model patient represents 409,071 € from the diagnosis of MM to death. The major cost burden is associated with the treatment, 155,645 € followed by the costs of productivity loss due to premature death, 127,611 €. Cost-of-illness studies provide an important view on the total burden of the disease in specific areas and are necessary for adequate decision-making process from the regulatory and reimbursement perspectiv

Keywords: multiple myeloma; cost-of-illness; direct costs; indirect costs; burden of disease
Published online: 27-Jan-2021
Year: 2021, Volume: 68, Issue: 2 Page From: 454, Page To: 464

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.